Connect with us

Hi, what are you looking for?

Investing

Eli Lilly stock price forecast ahead of obesity drug approval

Eli Lilly & Co (NYSE: LLY) has rallied over the past three months but a Bank of America analyst says it’s not out of room to run just yet.

Lilly stock should be worth $500

Geoff Meacham raised his price objective on the pharmaceutical behemoth in a research note this morning to $500 – up another 20% from here.

He expects the Eli Lilly stock to benefit as demand escalates for its obesity drug (Tirzepatide) that helped patients lose 16% of their body weight in a recent clinical study.

Consumer/social media trends bolster our confidence in Tirzepatide’s commercial opportunity, as patients seem very interested in anti-obesity medications, regardless of the administrative modality.

Eli Lilly now expects FDA approval for its weight loss drug by the end of this year.

Tirzepatide’s demand will increase

Geoff Meacham estimates demand for Lilly’s obesity drug to increase by 40% over the next seven years.

Mounjaro is not eligible for reimbursement under health insurance for now. But the BofA analyst is convinced that will change moving forward. All in all, he expects Tirzepatide to be a $20 billion drug by 2030.

In April, Eli Lilly & Co raised its outlook for the full financial year related partially to the weakening U.S. dollar. It now forecasts revenue to fall between $31.2 billion and $31.7 billion in fiscal 2023.

Earlier this month, famed investor Jim Cramer also dubbed the company’s Alzheimer’s drug a holy grail as Invezz reported here.

The post Eli Lilly stock price forecast ahead of obesity drug approval appeared first on Invezz.

You May Also Like

Economy

BlockSpan ICO: Accelerating NFT Innovation with Confidence The BlockSpan ICO aims to revolutionize the NFT space. To achieve that goal, it will provide an...

Investing

ZIM Integrated (NYSE: ZIM) stock price has crashed hard after the company canceled its dividend as the shipping industry recoils. The shares plunged to...

Investing

IDS share price has suffered a big reversal in the past few days as demand for the stock drops. Shares of Royal Mail’s parent...

Investing

Rolls-Royce (LON: RR) share price has been dead money in the past few days as investors react to the company’s turnaround and recent financial...



Disclaimer: Frequencytraders.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


Copyright © 2024 Frequencytraders.com